Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | CNR2 | P34972 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189074 | 0.89 | CNR1 (0.39) | CYP1A2CYP2C19CNR1CNR2RAB9A | |
| SCHEMBL3180947 | 0.88 | MMP13 (0.40) | CYP2C19CNR1CNR2ROCK2PPARA | |
| SCHEMBL13418625 | 0.88 | CNR1 (0.38) | CNR1CNR2RAB9AROCK2POLB | |
| SCHEMBL3197970 | 0.88 | IKBKB (0.39) | CNR1CNR2RAB9AROCK2POLB | |
| SCHEMBL3197647 | 0.87 | ACE2 (0.39) | CNR1CNR2RAB9ANPC1ROCK2 | |
| SCHEMBL3190881 | 0.87 | ROCK2 (0.41) | CNR1CNR2ROCK2SMN1; SMN2 | |
| SCHEMBL3190077 | 0.87 | ALPL (0.42) | CNR1CNR2RAB9AROCK2MAPT | |
| SCHEMBL3199031 | 0.87 | ALDH1A1 (0.43) | CYP1A2CYP2D6CYP2C19TSHRCNR1 | |
| SCHEMBL3198111 | 0.86 | ALDH1A1 (0.41) | CNR1CNR2RAB9AROCK2MAPT | |
| SCHEMBL3188631 | 0.85 | CNR1 (0.45) | CNR1CNR2RAB9AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074086-A1 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2006-04-06 | — | — | US | claimed |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-20060074086-A1 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074086-A1 | Phenyl derivatives and methods of use | CNR2, CNR1, GPR119 | CYP1A2 1830/4885CYP2D6 1533/4885CYP2C19 1669/4885 |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | CNR2, CNR1, GPR119 | CYP1A2 1830/4885CYP2D6 1533/4885CYP2C19 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.